Ziad Bakouny, MD, of Dana-Farber Cancer Institute, discusses the controversial and ill-defined role of cytoreductive nephrectomy in treating patients with metastatic renal cell carcinoma who have received targeted therapies or immune checkpoint inhibitors (Abstract 608).
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, describes a currently recruiting phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab vs nivolumab/ipilimumab for patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk (Abstract TPS767).
Ziad Bakouny, MD, of Dana-Farber Cancer Institute, discusses two types of renal cell cancer that are associated with poor prognosis. Because recent early data suggest these tumors respond well to immune checkpoint inhibitors, the authors characterized the tumors in an integrative molecular and clinical study (Abstract 715).
Neeraj Agarwal, MD, of the University of Utah Huntsman Cancer Institute, discusses trial findings that showed the combination of cabozantinib and atezolizumab had a tolerable safety profile and showed activity in men with metastatic disease. Further evaluation of cabozantinib and atezolizumab is planned in a phase III trial (Abstract 82).
Maha Hussain, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the first phase III clinical trial to demonstrate the feasibility of tissue-based genomic testing to preselect men with metastatic castration-resistant prostate cancer for targeted treatment and the superiority of the PARP inhibitor olaparib compared to enzalutamide or abiraterone (Abstract 195).
Julie N. Graff, MD, of Oregon Health & Science University and Knight Cancer Institute, discusses study findings that show pembrolizumab plus enzalutamide after progression on enzalutamide produced clinical activity and can lead to durable responses, with a manageable safety profile. The phase III KEYNOTE-641 trial will test patients who are enzalutamide-naive (Abstract 15).
